Watch: SpA and Interstitial Lung Disease Dr. Eric Ruderman discusses abstract OP0006 presented at EULAR 2023 in Milan, Italy. https://t.co/wsR3gv1jSr https://t.co/ULYbJeoFHi

Efficacy and Safety of Baricitinib in Lupus Nephritis Dr. Yuz Yusof discusses abstract OP0053 presented at EULAR 2023 in Milan, Italy. https://t.co/ebQ5RwG2po @Yuz6Yusof https://t.co/mUp7OXVK9K

Clinically suspect arthralgias: justified or artefact? At #EULAR23, the perfect platform was provided for an airing of grievances, in a debate entitled ‘Clinically suspect arthralgias: fact or myth’. Dr. Liew ( @drdavidliew ) summarizes the debate. https://t.co/wxLQlTVIaZ https://t.co/F6dJDZBrDk

Are T cells the missing link in pre-clinical RA? T cells are known to play a key role in RA pathogenesis and the diversity of the T cell repertoire is known to be reduced in RA. Dr.Najm ( @AurelieRheumo ) shares #EULAR23 presentations on this topic. https://t.co/qVyDp6Gs2y https://t.co/mqxNLIxShd

EULAR/PRES recos for sJIA & AOSD 🔹sJIA = AOSD l 👉 Unique name: Still’s disease 🔹Start IL1i or IL6i as soon as diagnosis made 🔹MAS ⚠️ 🔹Emerging issue: lung disease 👉Screening (HRCT if suspicion) #EULAR2023 Pr B Fautrel & F deBenedetti Key slides 👇🏼 NZ https://t.co/x1Snf8WI99

#Top #EULAR learnings #SLE #recommendations 1 Limit #prednisone 2 use #biologics early if poor prognosis 3 #lupus #nephritis - treat early with #belimumab or #voclosporin and more Rx in #RCTs #gamechanger https://t.co/JHQHu91tud

AOSD: Young vs. Elderly Onset AOSDis an autoinflammatory condition characterized by fevers, arthritis, and rash. It is considered an orphan disease because of its low prevalence - it is reported anywhere between 16 to 40 per ten million. https://t.co/bB2mpul3j7 https://t.co/ic6mY04ddF

Promising new therapies in SLE Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in. The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians. https://t.co/cdVw771HDs https://t.co/OYcN8hFLcP

An update on JAK inhibitors and cardiovascular risks Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors. https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK

Targeted therapies in Sjogren’s syndrome: are we close? There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies. https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2

EULAR 2023 – Day 3 Report https://t.co/qseMZiaHFq https://t.co/pnijisF9Jt

Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas Preliminary data from a lupus pregnancy LEGACY cohort presented at #EULAR23 are alarming. Dr. Bella Mehta ( @bella_mehta ) shares more. https://t.co/cY2G4s4yR0 https://t.co/isepEb8OXD